Outcomes in men denied access to a California public assistance program for prostate cancer

Jennifer T Anger1, Sally L Maliski, Tracey L Krupski

  • 1Department of Urology, David Geffen School of Medicine and School of Public Health, Los Angeles, CA, USA. janger@mednet.ucla.edu

Abstract

Insights

California

Area of Science:

  • Oncology
  • Public Health
  • Health Services Research

Background:

  • California's prostate cancer program, IMPACT, aimed to improve treatment access for low-income, uninsured men.
  • Budget cuts led to enrollment suspension and a waitlist, necessitating an assessment of patient outcomes.

Purpose of the Study:

  • To evaluate the impact of enrollment suspension on patient outcomes.
  • To compare health-related quality of life (HRQOL) between waitlisted and enrolled men.

Main Methods:

  • Matched cohort study comparing 83 waitlisted men with 83 enrolled men.
  • HRQOL assessed using validated instruments: UCLA Prostate Cancer Index (PCI-SF), SF-12, and Symptoms and Degrees of Distress Scale (SDS).
  • Self-efficacy measured using the Perceived Efficacy in Patient-Physician Interactions (PEPPI) Questionnaire.

Main Results:

  • Waitlisted men reported significantly higher symptom distress and lower self-efficacy at intake.
  • Waitlisted men had significantly less access to case managers, medications, nutrition information, and counseling.
  • P-values indicate statistical significance for observed differences.

Conclusions:

  • Denial of enrollment in the IMPACT program was associated with worse symptom distress and self-efficacy.
  • Reduced access to medical services may negatively impact HRQOL in waitlisted men.
  • The study underscores the critical need for public assistance programs for low-income prostate cancer patients.

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...